



Prescription Monitoring Program Advisory Committee

January 14, 2020

9:00 a.m.

**Texas State Board of Pharmacy
William Hobby Building, Room 2-225
333 Guadalupe Street
Austin, Texas**

MINUTES

Tuesday, January 14, 2020

I. Call to Order

Executive Director Allison Vordenbaumen Benz, R.Ph. M.S., called the meeting to order at 9:10 a.m. Committee Members present were C.M. Schade, M.D., Ph.D.; Troy Fiesinger, M.D., F.A.A.F.P.; Adam Bruggeman, M.D.; A.J. Kirk, M.D., F.F./E.M.T., F.A.A.E.M., F.A.C.E.P.; Mark DuVernois, D.D.S.; Matt Boutte, M.P.A.S., P.A.-C.; Doug Read, R.Ph, Pharm.D.; Raj Chhadua, R.Ph., Pharm.D.; Robert Hutchison Jr., R.Ph., Pharm.D.; Cherie Holmes-Henry; and Nora Belcher. Committee Member Michael Arambula, M.D., Pharm.D. was not present.

Staff present were Kerstin Arnold, General Counsel; Annette Graves, Assistant General Counsel; Megan Holloway, Assistant General Counsel; B.J. Slack, PMP Manager; Walquiria Sanchez, Staff Attorney; Ann Driscoll, Team Manager; and Heather Hernandez, Data Analyst.

II. Announcements

Ms. Benz made general announcements.

III. Review of H.B. 3284 regarding Committee Responsibilities

Ms. Benz reviewed the requirements of the law and the Committee responsibilities detailed therein.

IV. Introductions

- Election of Presiding Officer
 - Ms. Benz called for nominations for the Presiding Officer. A motion was made by Mr. Read to nominate Dr. Schade as Presiding Officer. The motion

was seconded by Dr. Bruggeman and passed unanimously.

- Dr. Schade introduced himself and the asked the other Committee members to introduce themselves.

V. Review of Texas PMP System

Jacob Cooper, Ken Cassell, and Sara White of Appriss Health presented information regarding the registration, use, and integration of the PMP system (AWARxE) along with new features, including NarxCare.

During the presentation, Dr. Schade requested that a report on any impact to the statistical data on nonfatal overdoses be presented after the deadline for mandatory checking.

Dr. Bruggeman asked Appriss Health to add FDA Blackbox warnings to reflect national guidelines to the Clinical Alerts. Black Box warnings normally appear on the label of a prescription medication to alert consumers and healthcare providers about safety concerns, such as serious adverse effects or life-threatening risks.

Dr. Fiesinger asked Appriss Health to add a patient facing component to NarxCare to help practitioners educate their patients and explain reasoning behind decisions. He also asked that the NarxCare scores be presented in a different format because he believes the score is hard to decipher upon quick glance and higher numbers may be seen as inherently negative, which could lead to discrimination.

Dr. Schade recessed the meeting at 11:47 a.m.

Dr. Schade reconvened the meeting at 1:03 p.m.

Committee Member Dr. Bruggeman left the meeting during the break.

VI. Funding for Integration

Ms. Benz discussed funding for the FY 2021-2022 biennium with the Committee.

VII. Discussion


Following discussion, Dr. Schade requested Ms. Belcher to provide information on using Medicaid cost savings for the PMP program to the Committee at the next meeting.

The Committee determined they would meet on the following dates:


- Monday, April 6, 2020, at 9 a.m.
- Monday, July 20, 2020, at 9 a.m.

Presiding Officer Dr. Schade adjourned the meeting at 2:47 p.m..

Approved



C.M. Schade, M.D., Ph.D.
Presiding Officer
July 20, 2020



Allison Vordenbaumen Benz, R.Ph., M.S.
Executive Director/Secretary
July 20, 2020